Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Merck KGaA. (3/26/14). "Press Release: Share Split to Make Merck Shares More Attractive to Private Investors. Shares to Be Divided in a Ratio of 2:1". Darmstadt.

Region Region Frankfurt am Main
  Country Germany
Organisation Organisation Merck KGaA
  Group Merck (DE) (Group)
Products Product CHEMICALS
  Product 2 pharmaceutical
Person Person Kley, Karl-Ludwig (Merck D 200705– Executive Chairman + CEO TO RETIRE 4/6)

> Shareholders to decide at the Annual General Meeting on May 9

Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors, today announced that it plans to propose to its shareholders at the Annual General Meeting on May 9 in Frankfurt am Main, Germany, a 2:1 share split.

"Over the past three years, the value of Merck shares has doubled, mainly thanks to the resolute implementation of our 'Fit for 2018' transformation and growth program. Merck is in excellent financial health. For one year now, the price of Merck shares has consistently been well over € 100. Through a share split, we want to make Merck shares more attractive to private investors," said Karl-Ludwig Kley, Chairman of the Executive Board.

One existing no-par value share of the company with a pro rata amount of the share capital of € 2.60 is to be split into two no-par value shares, each with a pro rata amount of the share capital of € 1.30. This liquidity-supporting measure, which will not alter the value of the company, would double the number of Merck shares while the share price will be divided in half. No new funds will be added to the company. The share capital of the company amounting to € 168,014,927.60 is currently divided into 64,621,126 no-par value shares.

On March 25, 2014, Merck shares (ISIN: DE 000 659 9905, WKN: 659 990) closed at € 120.95 in XETRA trading. The invitation to the Annual General Meeting and further information can be found here.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website Please go to to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

Record changed: 2017-04-02


Picture Lipotype Lipidomics Drug Biomarker Discovery iito 600x60px

More documents for Merck (DE) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

» top